Top in endocrinology: New contraceptive pill, disposing diabetes materials

Last week, the FDA approved Nextstellis, the first combination contraceptive tablet containing naturally occurring estrogen from a plant source. It was the top story in endocrinology.

Another top story was about concerns regarding the disposal of diabetes materials, including packaging, test strips, plastic and sharps.

Read these and more top stories in endocrinology below:

FDA approves novel oral contraceptive pill

The FDA approved a combination drospirenone and estetrol tablet (Nextstellis, Mayne Pharma) for the prevention of pregnancy, according to an industry press release. It is the only oral contraceptive to contain estetrol, described as a native estrogen with selective actions in tissues. Read more.

Plastics, sharps diabetes waste require conscious disposal

Among the burdens of managing diabetes is responsibly discarding all the packaging, test strips, plastic and sharps. Manufacturers of new technologies are working to reduce waste, but concerns about disposal remain. Read more.

Mindfulness, acceptance-based diabetes education may reduce distress, lower HbA1c

Mindfulness- and acceptance-based approaches to diabetes education may lower diabetes distress and HbA1c more than usual care for adults with type 2 diabetes, according to findings published in Diabetic Medicine. Read more.

Timing of HT during puberty influences bone development in transgender adolescents

Transgender adolescents treated with gender-affirming hormone therapy early in puberty experience bone development more similar to that of their experienced gender compared with their gender assigned at birth, according to study data. Read more.

Most physicians suppress TSH in patients with intermediate-, low-risk thyroid cancer

Most physicians treating patients with thyroid cancer said they would suppress thyroid-stimulating hormone in those with low- and intermediate-risk thyroid cancer, according to a study published in Thyroid. Read more.